Insulin glargine biosimilar (Incepta Pharmaceuticals)

甘精胰岛素生物类似药 (Incepta Pharmaceuticals)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInsulin glargine biosimilar (Incepta Pharmaceuticals)
Drug Alias Name甘精胰岛素生物仿制药 (Incepta Pharmaceuticals)
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
Global Approved IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
Approved Indications in ChinaN/A
Original Approved Country/TerritoryBangladesh
Original Approved Date2012/08/01
Country/TerritoryBangladesh
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesIncepta Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesIncepta Pharmaceuticals Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2Diabetes Mellitus, Type 1
Inactive IndicationsN/A

Other Information

ATC CodeA10AE04
Related LinksN/A